EFSA health claim opinion

‘eye q’ omega-3 not bright enough for EFSA


- Last updated on GMT

May this child never have to read the NHCR text...
May this child never have to read the NHCR text...

Related tags Eicosapentaenoic acid Omega-3 fatty acid Nda

A DHA/EPA/GLA omega-3 supplement will not improve a child’s reading ability, the EU’s central food science agency has ruled.

In a new health claim opinion EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) found data lacking to back Swiss firm Vifor’s assertion that its ‘eye Q’ supplement could boost reading capacity in children between the ages of three and 13.

Vifor submitted four studies under the children's claim-focused article 14 of the nutrition and health claims regulation (NHCR) to back its claim that eye Q could facilitate “improvement in reading ability.“

The NDA found flaws in three of them including lack of a control and lack of testing for multiplicity of outcomes. They were all dismissed.

One of the studies used EFSA-backed measures like the Wechsler Objective Reading Dimensions (WORD) test to determine if the reading ability of 241 British 6-12 year-olds from diverse backgrounds improved versus placebo over six months.

For three months, half of the children were given eye Q, half an olive oil solution. In the next three months all children were given eye Q, a design the NDA said meant the second period findings were not assessable for a lack of control. In dismissing its overall findings the NDA added the trial failed to address interaction between intervention and schools on reading ability in its statistical analysis.

Another study used measures like the Wide Range Achievement Test: Fourth Edition (WRAT4) to assess changes in reading ability of 154 9-10 year olds given eye Q or placebo with the same 3+3 months design the NDA again dismissed.

In the fourth study – a double-blind, placebo-controlled parallel intervention – 408 rural Australian children aged 3-13 were given either six eye Q capsules or an olive oil placebo for 20 weeks. A second phase where  they all consumed eye Q was dismissed by the NDA for the same reasons as above.

But even in the assessable first 20 weeks the NDA said there was no significant difference between the eye Q and placebo groups.

It therefore rejected the proposition.

The NDA opinion is here​.


According to Vifor children need to consume 558 mg of eicosapentaenoic acid (EPA), 174 mg of docosahexaenoic acid (DHA) and 60 mg of gamma-linolenic acid (GLA) – a ratio of 9:3:1 – to achieve the desired effect.

Its formulations typically arrive in:

  • capsules or chewable capsules: 93 mg EPA, 29 mg DHA, 10 mg GLA per capsule;
  • triple strength capsules: 279 mg EPA, 87 mg DHA, 30 mg GLA per capsule;
  • liquid formulation: 186 mg EPA, 58 mg DHA, 20 mg GLA per 5 ml.

Eye Q has had several cognitive claims rejected under the NHCR over the years, dating back to 2008, when the new law began to take effect across the EU.

Related news

Show more

Related products

show more

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 08-May-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Optimize Nutritional Value with DuraLipo™

Optimize Nutritional Value with DuraLipo™

Content provided by INNOBIO Corporation Limited | 02-May-2024 | White Paper

INNOBIO's DuraLipo™ products encapsulates active ingredients within phospholipids, forming a genuine phospholipid bilayer structure.

Krill oil supports six key areas of healthy aging

Krill oil supports six key areas of healthy aging

Content provided by Aker BioMarine | 23-Feb-2024 | White Paper

The global population is getting older—according to WHO by 2050 the world’s population over 60 years will double and the population above 80 years will...

Related suppliers

Follow us


View more